Brief: Osmotica Pharmaceuticals PLC Reports Fourth Quarter And Full Year 2020 Results
30/03/2021 21:21
March 30 (Reuters) - Osmotica Pharmaceuticals PLC OSMT.O :
* REPORTS FOURTH QUARTER AND FULL YEAR 2020 RESULTS AND
PROVIDES
BUSINESS UPDATE
* Q4 REVENUE $34.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF
$35.6
MILLION
* OSMOTICA PHARMACEUTICALS - CASH, EQUIVALENTS WERE $114.1
MILLION, AND DEBT (NET OF DEFERRED FINANCING COSTS) WAS $219.5
MILLION AS OF DEC 31, 2020
* INITIATED STRATEGIC REVIEW IN Q4
Source text for Eikon: ID:nGNX5Bw0vr
Further company coverage: OSMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RVL Pharmaceuticals
See all newsBrief: RVL Pharmaceuticals Says High Court Of Ireland Made A Winding Up Order In Respect Of Co On Feb 12
Brief: RVL Pharmaceuticals Says Co Issued Petition In Central Office Of High Court In Ireland To Wind Up Company
Brief: RVL Completes Financial Restructuring
Brief: Rvl Pharmaceuticals PLC Received Delisting Notice From Listing Qualifications Department Of Nasdaq Stock Market Llc
U.S. STOCKS ON THE MOVE-Cerevel Therapeutics, Scholar Rock, Helius